[
  {
    "ts": null,
    "headline": "I-Mab Biopharma Stock: Caution Warranted After Huge Surge",
    "summary": "I-Mab Biopharma surged on promising givastomig results in gastric cancer. Click for my updated look at IMAB stock and why I am remaining neutral.",
    "url": "https://finnhub.io/api/news?id=b80c05aac930259c2b7cffa31faa8a5ffd8940a4dfeb13891be07fce641a90a0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760465752,
      "headline": "I-Mab Biopharma Stock: Caution Warranted After Huge Surge",
      "id": 137089117,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295160689/image_1295160689.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "I-Mab Biopharma surged on promising givastomig results in gastric cancer. Click for my updated look at IMAB stock and why I am remaining neutral.",
      "url": "https://finnhub.io/api/news?id=b80c05aac930259c2b7cffa31faa8a5ffd8940a4dfeb13891be07fce641a90a0"
    }
  },
  {
    "ts": null,
    "headline": "Amgen (AMGN) Announces Launch of AmgenNow",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the Best Wide Moat Stocks to Buy Right Now. The company possesses a wide economic moat, which is backed by its intellectual property and brand reputation. On October 6, the company announced the launch of AmgenNow, which is a new direct-to-patient program starting with Repatha® (evolocumab). This comes after the […]",
    "url": "https://finnhub.io/api/news?id=ac7a082fa0697159109906ea7f8b119169e675a3c7d3a9e294d03864c768b79d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760461575,
      "headline": "Amgen (AMGN) Announces Launch of AmgenNow",
      "id": 137085915,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the Best Wide Moat Stocks to Buy Right Now. The company possesses a wide economic moat, which is backed by its intellectual property and brand reputation. On October 6, the company announced the launch of AmgenNow, which is a new direct-to-patient program starting with Repatha® (evolocumab). This comes after the […]",
      "url": "https://finnhub.io/api/news?id=ac7a082fa0697159109906ea7f8b119169e675a3c7d3a9e294d03864c768b79d"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again",
    "summary": "Johnson & Johnson's Q3 2025 earnings beat forecasts, with strong oncology sales and raised guidance. Click for my updated look at JNJ stock prospects.",
    "url": "https://finnhub.io/api/news?id=2d338e41d2ed5636b2c4f31ccf41db9670c3f47ddb04a5f8f264d19468c2cead",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760432295,
      "headline": "Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again",
      "id": 137076426,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2212125573/image_2212125573.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson's Q3 2025 earnings beat forecasts, with strong oncology sales and raised guidance. Click for my updated look at JNJ stock prospects.",
      "url": "https://finnhub.io/api/news?id=2d338e41d2ed5636b2c4f31ccf41db9670c3f47ddb04a5f8f264d19468c2cead"
    }
  },
  {
    "ts": null,
    "headline": "SCHD: The Best Time In Years To Buy This Dividend Powerhouse",
    "summary": "Discover why SCHD's recent underperformance could signal opportunity. Learn why now may be the best time to invest in SCHD.",
    "url": "https://finnhub.io/api/news?id=d87cd0e3b05f44c68962de7185c5a3ebeb759ee76eb9d23f41c8b88286222a71",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760428824,
      "headline": "SCHD: The Best Time In Years To Buy This Dividend Powerhouse",
      "id": 137076239,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1480116578/image_1480116578.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Discover why SCHD's recent underperformance could signal opportunity. Learn why now may be the best time to invest in SCHD.",
      "url": "https://finnhub.io/api/news?id=d87cd0e3b05f44c68962de7185c5a3ebeb759ee76eb9d23f41c8b88286222a71"
    }
  }
]